Adjunctive treatment with the mammalian target of rapamycin (mTOR) inhibitor everolimus (Afinitor, Novartis) not only decreases the frequency of seizures associated with tuberous sclerosis but also ...

A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with sporadic and hereditary papillary renal cell carcinoma: Final efficacy, safety, and PD results.

VANCOUVER -- The mTOR inhibitor everolimus (Afinitor) diminished seizure frequency in patients with tuberous sclerosis who'd been refractory to other therapy, researchers reported here. In a phase III ...

Phase III trial of Novartis drug Afinitor® met primary endpoint of reducing SEGA tumor size in patients with tuberous sclerosis Largest Phase III study in tuberous sclerosis complex (TSC) showed 35% ...

The US Food and Drug Administration (FDA) has approved everolimus tablets for oral suspension (Afinitor Disperz, Novartis) for the adjunctive treatment of adults and children aged 2 years and older ...

Novartis announced results from its Phase 3 EXIST-1 study of Afinitor (everolimus) for the treatment of patients with subependymal giant cell astrocytomas (SEGAs) associated with tuberous sclerosis ...

The drug everolimus has been shown to significantly reduce the frequency of seizures in patients with treatment-resistant epilepsy and tuberous sclerosis complex (TSC) -- a genetic disease that causes ...

Novartis drug Votubia® approved in the EU as first medication to treat patients with non-cancerous kidney tumors associated with TSC Prior to this approval, surgical intervention was the only option ...

Toxicity of 131I-MIBG combined with high-dose chemotherapy in children with refractory neuroblastoma. This is an ASCO Meeting Abstract from the 2011 ASCO Annual Meeting I. This abstract does not ...

The development of stomatitis in patients taking everolimus did not appear to adversely affect PFS and, thus, should not be considered a hindrance to the drug’s administration, according to the ...

In an international study, the drug everolimus has been shown to significantly reduce the frequency of seizures in patients with treatment-resistant epilepsy and tuberous sclerosis complex (TSC) -- a ...